BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meng F, Wang J, Yeo Y. Nucleic acid and oligonucleotide delivery for activating innate immunity in cancer immunotherapy. J Control Release 2022;345:586-600. [PMID: 35351528 DOI: 10.1016/j.jconrel.2022.03.045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y. Nanotechnology for next-generation cancer immunotherapy: State of the art and future perspectives. J Control Release 2023;356:14-25. [PMID: 36805873 DOI: 10.1016/j.jconrel.2023.02.016] [Reference Citation Analysis]
2 Kalita T, Dezfouli SA, Pandey LM, Uludag H. siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases. Pharmaceutics 2022;14. [PMID: 36432711 DOI: 10.3390/pharmaceutics14112520] [Reference Citation Analysis]
3 Nedorezova DD, Dubovichenko MV, Belyaeva EP, Grigorieva ED, Peresadina AV, Kolpashchikov DM. Specificity of oligonucleotide gene therapy (OGT) agents. Theranostics 2022;12:7132-57. [PMID: 36276652 DOI: 10.7150/thno.77830] [Reference Citation Analysis]